{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T14:42:12Z","timestamp":1777819332330,"version":"3.51.4"},"reference-count":51,"publisher":"International Society of Endovascular Specialists","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Endovascular Therapy"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1583\/04-1498r.1","type":"journal-article","created":{"date-parts":[[2005,6,8]],"date-time":"2005-06-08T14:16:08Z","timestamp":1118240168000},"page":"332-342","source":"Crossref","is-referenced-by-count":3,"title":["<b>Short-term Rapamycin for Inhibition of Neointima Formation After Balloon-Mediated Aortic Injury in Rats:<\/b>\n                    Is There a Window of Opportunity for Systemic Prophylaxis of Restenosis?"],"prefix":"10.1583","volume":"12","author":[{"given":"Thomas","family":"Jahnke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz K. W.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Bolte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit","family":"Heuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Karbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Brossmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"M\u00fcller-H\u00fclsbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"527","reference":[{"key":"i1545-1550-12-3-332-b1","doi-asserted-by":"crossref","unstructured":"B. R. Morgenstern, G. I. Getrajdman, and K. J. Laffey .et al.Total occlusion of the femoropopliteal artery: high technical success rate of conventional balloon angioplasty., Radiology, 1998 .172 :937 \u2013940 .","DOI":"10.1148\/172.3.937"},{"key":"i1545-1550-12-3-332-b2","doi-asserted-by":"crossref","unstructured":"J. W. Currier, and D. P. Faxon .Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? J Am Coll Cardiol, 1995 .25 :516 \u2013520 .","DOI":"10.1016\/0735-1097(95)98445-J"},{"key":"i1545-1550-12-3-332-b3","doi-asserted-by":"crossref","unstructured":"M. Hintner, and C. Behrmann .Long-term results of angioplasties of pelvic and leg blood vessels [in German]., Rofo, 2000 .172 :775 \u2013779 .","DOI":"10.1055\/s-2000-7215"},{"key":"i1545-1550-12-3-332-b4","doi-asserted-by":"crossref","unstructured":"S. Glagov, Intimal hyperplasia, vascular modeling, and the restenosis problem., Circulation, 1994 .89 :2888 \u20132889 .","DOI":"10.1161\/01.CIR.89.6.2888"},{"key":"i1545-1550-12-3-332-b5","doi-asserted-by":"crossref","unstructured":"M. Kearney, A. Pieczek, and L. Haley .et al.Histopathology of in-stent restenosis in patients with peripheral artery disease., Circulation, 1997 .95 :1998 \u20132002 .","DOI":"10.1161\/01.CIR.95.8.1998"},{"key":"i1545-1550-12-3-332-b6","doi-asserted-by":"crossref","unstructured":"K. H. Barth, R. Virmani, and J. Froelich .et al.Paired comparison of vascular wall reactions to Palmaz stents, Strecker tantalum stents, and Wallstents in canine iliac and femoral arteries., Circulation, 1996 .93 :2161 \u20132169 .","DOI":"10.1161\/01.CIR.93.12.2161"},{"key":"i1545-1550-12-3-332-b8","doi-asserted-by":"crossref","unstructured":"D. P. Faxon, Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group., J Am Coll Cardiol, 1995 .25 :362 \u2013369 .","DOI":"10.1016\/0735-1097(94)00368-Z"},{"key":"i1545-1550-12-3-332-b9","unstructured":"A. Kastrati, H. Schuhlen, and J. Hausleiter .et al.Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial., Circulation, 1997 .96 :462 \u2013467 ."},{"key":"i1545-1550-12-3-332-b10","doi-asserted-by":"crossref","unstructured":"M. E. Bertrand, E. P. McFadden, and J. C. Fruchart .et al.Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty., J Am Coll Cardiol, 1997 .30 :863 \u2013869 .","DOI":"10.1016\/S0735-1097(97)00259-3"},{"key":"i1545-1550-12-3-332-b11","doi-asserted-by":"crossref","unstructured":"S. J. Boccuzzi, W. S. Weintraub, and A. S. Kosinski .et al.Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial)., Am J Cardiol, 1998 .81 :632 \u2013636 .","DOI":"10.1016\/S0002-9149(97)00980-6"},{"key":"i1545-1550-12-3-332-b12","doi-asserted-by":"crossref","unstructured":"P. W. Serruys, D. P. Foley, and B. Hofling .et al.Carvedilol for prevention of restenosis after directional coronary atherectomy: final results of the European carvedilol atherectomy restenosis (EUROCARE) trial., Circulation, 2000 .101 :1512 \u20131518 .","DOI":"10.1161\/01.CIR.101.13.1512"},{"key":"i1545-1550-12-3-332-b13","doi-asserted-by":"crossref","unstructured":"T. Suzuki, G. Kopia, and S. Hayashi .et al.Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model., Circulation, 2001 .104 :1188 \u20131193 .","DOI":"10.1161\/hc3601.093987"},{"key":"i1545-1550-12-3-332-b14","doi-asserted-by":"crossref","unstructured":"A. Farb, P. F. Heller, and S. Shroff .et al.Pathological analysis of local delivery of paclitaxel via a polymer-coated stent., Circulation, 2001 .104 :473 \u2013479 .","DOI":"10.1161\/hc3001.092037"},{"key":"i1545-1550-12-3-332-b15","doi-asserted-by":"crossref","unstructured":"R. Virmani, A. Farb, and G. Guagliumi .et al.Drug-eluting stents: caution and concerns for long-term outcome., Coron Artery Dis, 2004 .15 :313 \u2013318 .","DOI":"10.1097\/00019501-200409000-00003"},{"key":"i1545-1550-12-3-332-b16","doi-asserted-by":"crossref","unstructured":"F. Liistro, G. Stankovic, and C. Di Mario .et al.First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome., Circulation, 2002 .105 :1883 \u20131886 .","DOI":"10.1161\/01.CIR.0000016042.69606.61"},{"key":"i1545-1550-12-3-332-b17","doi-asserted-by":"crossref","unstructured":"F. F\u00e4ndrich, M. Ruhnke, and B. Dresske .et al.Tolerance-inducing strategies in transplantation surgery-current status and perspectives., Langenbecks Arch Surg, 2004 .389 :60 \u201366 .","DOI":"10.1007\/s00423-003-0415-1"},{"key":"i1545-1550-12-3-332-b18","doi-asserted-by":"crossref","unstructured":"T. Jahnke, U. Karbe, and F. K. Sch\u00e4fer .et al.Characterization of a new double-injury restenosis model in the rat aorta., J Endovasc Ther, 2005 .12 :318 \u2013331 .","DOI":"10.1583\/04-1466MR.1"},{"key":"i1545-1550-12-3-332-b19","doi-asserted-by":"crossref","unstructured":"J. L. Cordell, B. Falini, and W. N. Erber .et al.Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes)., J Histochem Cytochem, 1984 .32 :219 \u2013229 .","DOI":"10.1177\/32.2.6198355"},{"key":"i1545-1550-12-3-332-b20","doi-asserted-by":"crossref","unstructured":"L. Capron, J. Jarnet, and D. Heudes .et al.Repeated balloon injury of rat aorta., Arterioscler Thromb Vasc Biol, 1997 .17 :1649 \u20131656 .","DOI":"10.1161\/01.ATV.17.9.1649"},{"key":"i1545-1550-12-3-332-b21","doi-asserted-by":"crossref","unstructured":"M. Foegh, and R. Virmani .Molecular biology of intimal proliferation., Curr Opin Cardiol, 1993 .8 :938 \u2013955 .","DOI":"10.1097\/00001573-199311000-00007"},{"key":"i1545-1550-12-3-332-b22","doi-asserted-by":"crossref","unstructured":"D. H. Gorski, D. F. LePage, and C. V. Patel .et al.Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G0\/G1 transition in vascular smooth muscle cells., Mol Cell Biol, 1993 .13 :3722 \u20133733 .","DOI":"10.1128\/MCB.13.6.3722"},{"key":"i1545-1550-12-3-332-b23","doi-asserted-by":"crossref","unstructured":"W. Casscells, D. A. Lappi, and A. Baird .Molecular atherectomy for restenosis., Trends Cardiovasc Med, 1993 .3 :235 .","DOI":"10.1016\/1050-1738(93)90045-8"},{"key":"i1545-1550-12-3-332-b24","doi-asserted-by":"crossref","unstructured":"A. Lafont, and D. Faxon .Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res, 1998 .39 :50 \u201359 .","DOI":"10.1016\/S0008-6363(98)00109-6"},{"key":"i1545-1550-12-3-332-b25","doi-asserted-by":"crossref","unstructured":"J. W. Moses, M. B. Leon, and J. J. Popma .et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery., N Engl J Med, 2003 .349 :1315 \u20131323 .","DOI":"10.1056\/NEJMoa035071"},{"key":"i1545-1550-12-3-332-b26","doi-asserted-by":"crossref","unstructured":"R. Virmani, F. Liistro, and G. Stankovic .et al.Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans., Circulation, 2002 .106 :2649 \u20132651 .","DOI":"10.1161\/01.CIR.0000041632.02514.14"},{"key":"i1545-1550-12-3-332-b27","doi-asserted-by":"crossref","unstructured":"D. P. Faxon, Systemic drug therapy for restenosis: \u201cd\u00e9j\u00e0 vu all over again.\u201d., Circulation, 2002 .106 :2296 \u20132298 .","DOI":"10.1161\/01.CIR.0000038412.38399.D5"},{"key":"i1545-1550-12-3-332-b28","doi-asserted-by":"crossref","unstructured":"C. Vezina, A. Kudelski, and S. N. Sehgal .Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle., J Antibiot (Tokyo), 1975 .28 :721 \u2013726 .","DOI":"10.7164\/antibiotics.28.721"},{"key":"i1545-1550-12-3-332-b29","doi-asserted-by":"crossref","unstructured":"S. N. Sehgal, H. Baker, and C. Vezina .Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization., J Antibiot (Tokyo), 1975 .28 :727 \u2013732 .","DOI":"10.7164\/antibiotics.28.727"},{"key":"i1545-1550-12-3-332-b30","doi-asserted-by":"crossref","unstructured":"D. Mancini, S. Pinney, and D. Burkhoff .et al.Use of rapamycin slows progression of cardiac transplantation vasculopathy., Circulation, 2003 .108 :48 \u201353 .","DOI":"10.1161\/01.CIR.0000070421.38604.2B"},{"key":"i1545-1550-12-3-332-b31","doi-asserted-by":"crossref","unstructured":"S. N. Sehgal, Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression., Clin Biochem, 1998 .31 :335 \u2013340 .","DOI":"10.1016\/S0009-9120(98)00045-9"},{"key":"i1545-1550-12-3-332-b32","doi-asserted-by":"crossref","unstructured":"M. Poon, S. O. Marx, and R. Gallo .et al.Rapamycin inhibits vascular smooth muscle cell migration., J Clin Invest, 1996 .98 :2277 \u20132283 .","DOI":"10.1172\/JCI119038"},{"key":"i1545-1550-12-3-332-b33","doi-asserted-by":"crossref","unstructured":"S. E. Burke, N. L. Lubbers, and Y. W. Chen .et al.Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin., J Cardiovasc Pharmacol, 1999 .33 :829 \u2013835 .","DOI":"10.1097\/00005344-199906000-00001"},{"key":"i1545-1550-12-3-332-b34","doi-asserted-by":"crossref","unstructured":"R. Gallo, A. Padurean, and T. Jayaraman .et al.Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle., Circulation, 1999 .99 :2164 \u20132167 .","DOI":"10.1161\/01.CIR.99.16.2164"},{"key":"i1545-1550-12-3-332-b35","doi-asserted-by":"crossref","unstructured":"J. Hirosumi, A. Nomoto, and Y. Ohkubo .et al.Inflammatory responses in cuff-induced atherosclerosis in rabbits., Atherosclerosis, 1987 .64 :243 \u2013254 .","DOI":"10.1016\/0021-9150(87)90252-8"},{"key":"i1545-1550-12-3-332-b36","doi-asserted-by":"crossref","unstructured":"M. Moroi, L. Zhang, and T. Yasuda .et al.Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice., J Clin Invest, 1998 .101 :1225 \u20131232 .","DOI":"10.1172\/JCI1293"},{"key":"i1545-1550-12-3-332-b37","doi-asserted-by":"crossref","unstructured":"M. Akishita, M. Horiuchi, and H. Yamada .et al.Inflammation influences vascular remodeling through AT2 receptor expression and signalling., Physiol Genomics, 2000 .2 :13 \u201320 .","DOI":"10.1152\/physiolgenomics.2000.2.1.13"},{"key":"i1545-1550-12-3-332-b38","doi-asserted-by":"crossref","unstructured":"L. Wu, M. Iwai, and H. Nakagami .et al.Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type l receptor blockade with valsartan in the improvement of inflammation-induced vascular injury., Circulation, 2001 .104 :2716 \u20132721 .","DOI":"10.1161\/hc4601.099404"},{"key":"i1545-1550-12-3-332-b39","doi-asserted-by":"crossref","unstructured":"S. O. Marx, T. Jayaraman, and L. O. Go .et al.Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells., Circ Res, 1995 .76 :412 \u2013417 .","DOI":"10.1161\/01.RES.76.3.412"},{"key":"i1545-1550-12-3-332-b40","doi-asserted-by":"crossref","unstructured":"A. Farb, M. John, and E. Acampado .et al.Oral everolimus inhibits in-stent neointimal growth., Circulation, 2002 .106 :2379 \u20132384 .","DOI":"10.1161\/01.CIR.0000033973.06059.04"},{"key":"i1545-1550-12-3-332-b41","doi-asserted-by":"crossref","unstructured":"N. Uchimura, G. B. Perera, and R. M. Fujitani .et al.Dose-dependent inhibition of myointimal hyperplasia by orally administered rapamycin., Ann Vasc Surg, 2004 .18 :172 \u2013177 .","DOI":"10.1007\/s10016-004-0010-0"},{"key":"i1545-1550-12-3-332-b42","doi-asserted-by":"crossref","unstructured":"P. S. Brara, M. Moussavian, and M. A. Grise .et al.Pilot trial of oral rapamycin for recalcitrant restenosis., Circulation, 2003 .107 :1722 \u20131724 .","DOI":"10.1161\/01.CIR.0000066282.05411.17"},{"key":"i1545-1550-12-3-332-b43","doi-asserted-by":"crossref","unstructured":"J. Hausleiter, A. Kastrati, and J. Mehilli .et al.Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis. The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial., Circulation, 2004 .110 :790 \u2013795 .","DOI":"10.1161\/01.CIR.0000138935.17503.35"},{"key":"i1545-1550-12-3-332-b44","unstructured":"A. E. Rodriguez, M. R. Alemparte, and C. F. Vigo .et al.Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial)., J Invasive Cardiol, 2003 .15 :581 \u2013584 ."},{"key":"i1545-1550-12-3-332-b45","doi-asserted-by":"crossref","unstructured":"R. Waksman, A. E. Ajani, and A. D. Pichard .et al.Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study., J Am Coll Cardiol, 2004 .44 :1386 \u20131392 .","DOI":"10.1016\/S0735-1097(04)01447-0"},{"key":"i1545-1550-12-3-332-b46","doi-asserted-by":"crossref","unstructured":"G. Li, S. J. Chen, and S. Oparil .et al.Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries., Circulation, 2000 .101 :1362 \u20131365 .","DOI":"10.1161\/01.CIR.101.12.1362"},{"key":"i1545-1550-12-3-332-b47","doi-asserted-by":"crossref","unstructured":"S. Oparil, S. J. Chen, and Y. F. Chen .et al.Estrogen attenuates the adventitial contribution to neointimal formation in injured rat carotid arteries., Cardiovasc Res, 1999 .44 :608 \u2013614 .","DOI":"10.1016\/S0008-6363(99)00240-0"},{"key":"i1545-1550-12-3-332-b48","unstructured":"A. Bayes-Genis, B. Kantor, and P. C. Keelan .et al.Restenosis and hyperplasia: animal models., Curr Interv Cardiol Rep, 2000 .2 :303 \u2013308 ."},{"key":"i1545-1550-12-3-332-b49","doi-asserted-by":"crossref","unstructured":"V. L. Herreia, S. C. Makrides, and H. X. Xie .et al.Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein., Nat Med, 1999 .5 :1383 \u20131389 .","DOI":"10.1038\/70956"},{"key":"i1545-1550-12-3-332-b50","doi-asserted-by":"crossref","unstructured":"A. V. Finn, H. K. Gold, and A. Tang .et al.A novel rat model of carotid artery stenting for the understanding of restenosis in metabolic disease., J Vasc Res, 2002 .39 :414 \u2013425 .","DOI":"10.1159\/000064518"},{"key":"i1545-1550-12-3-332-b51","doi-asserted-by":"crossref","unstructured":"J. E. Leidenfrost, M. F. Khan, and K. P. Boc .et al.A model of primary atherosclerosis and post-angioplasty restenosis in mice., Am J Pathol, 2003 .163 :773 \u2013778 .","DOI":"10.1016\/S0002-9440(10)63704-2"},{"key":"i1545-1550-12-3-332-b52","doi-asserted-by":"crossref","unstructured":"J. H. Von der Thusen, M. L. Fekkes, and R. Passier .et al.Adenoviral transfer of endothelial nitric oxide synthase attenuates lesion formation in a novel murine model of postangioplasty restenosis., Arterioscler Thromb Vasc Biol, 2004 .24 :357 \u2013362 .","DOI":"10.1161\/01.ATV.0000114235.51044.92"}],"container-title":["Journal of Endovascular Therapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:27:40Z","timestamp":1777498060000},"score":1,"resource":{"primary":{"URL":"http:\/\/jet.sagepub.com\/lookup\/doi\/10.1583\/04-1498R.1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1583\/04-1498R.1"],"URL":"https:\/\/doi.org\/10.1583\/04-1498r.1","relation":{},"ISSN":["1526-6028","1545-1550"],"issn-type":[{"value":"1526-6028","type":"print"},{"value":"1545-1550","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}